Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells (original) (raw)

• Dieci MV, Arnedos M, Andre F, Soria JC . Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264–279.
  Article CAS Google Scholar
• Katoh M, Nakagama H FGF receptors: cancer biology and therapeutics. Med Res Revi 2013; 34: 280–300.
  Article Google Scholar
• Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116–129.
  Article CAS Google Scholar
• Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
  Article CAS Google Scholar
• Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–525.
  Article CAS Google Scholar
• Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57: 4360–4367.
  CAS PubMed Google Scholar
• Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340–2348.
  Article CAS Google Scholar
• Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013–2023.
  Article CAS Google Scholar
• van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002; 10: 819–824.
  Article CAS Google Scholar
• Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105: 8713–8717.
  Article CAS Google Scholar
• Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM et al. Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Res 2013; 73: 5195–5205.
  Article CAS Google Scholar
• Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.
  Article CAS Google Scholar
• Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729–736.
  Article CAS Google Scholar
• Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231–1235.
  Article CAS Google Scholar
• Williams SV, Hurst CD, Knowles MA . Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013; 22: 795–803.
  Article CAS Google Scholar
• Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013; 230: 270–276.
  Article CAS Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636–647.
  Article CAS Google Scholar
• Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA . Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75–82.
  Article CAS Google Scholar
• Lemieux S, Hadden MK . Targeting the fibroblast growth factor receptors for the treatment of cancer. Anticancer Agents Med Chem 2013; 13: 748–761.
  Article CAS Google Scholar
• Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19: 3693–3702.
  Article CAS Google Scholar
• Wolf J, LoRusso PM, Camidge RD, Perez JM, Tabernero J, Hidalgo M et al. Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 72.
  Article Google Scholar
• Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066–7083.
  Article CAS Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 2: 1118–1133.
  Article CAS Google Scholar
• Garraway LA, Janne PA . Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2: 214–226.
  Article CAS Google Scholar
• Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov 2012; 2: 948–959.
  Article CAS Google Scholar
• Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A et al. Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer. Cancer Discov 2013; 3: 1058–1071.
  Article CAS Google Scholar
• Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013; 32: 3059–3070.
  Article CAS Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
  Article Google Scholar
• Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
  Article CAS Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043.
  Article CAS Google Scholar
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505–509.
  Article CAS Google Scholar
• Schlessinger J . Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669–672.
  Article CAS Google Scholar
• Bublil EM, Yarden Y . The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124–134.
  Article CAS Google Scholar
• Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 2013; 73: 3051–3061.
  Article CAS Google Scholar
• Citri A, Skaria KB, Yarden Y . The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 54–65.
  Article CAS Google Scholar
• Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500–504.
  Article CAS Google Scholar
• Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008; 25: 685–693.
  Article Google Scholar
• Winter SF, Acevedo VD, Gangula RD, Freeman KW, Spencer DM, Greenberg NM . Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 2007; 26: 4897–4907.
  Article CAS Google Scholar
• Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genet 2012; 44: 852–860.
  Article CAS Google Scholar
• Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ . Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS ONE 2013; 8: e57284.
  Article CAS Google Scholar
• Jenndahl LE, Isakson P, Baeckstrom D . c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int J Oncol 2005; 27: 439–448.
  CAS PubMed Google Scholar
• Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B et al. 14-3-3zeta cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009; 16: 195–207.
  Article CAS Google Scholar
• Kim J, Jeong H, Lee Y, Kim C, Kim H, Kim A . HRG-beta1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells. BMC Cancer 2013; 13: 383.
  Article CAS Google Scholar
• Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 2013; 123: 2155–2168.
  Article CAS Google Scholar
• Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3: 520–533.
  Article CAS Google Scholar
• Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283–1298.
  Article CAS Google Scholar